An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

Veronica Mollica, Vincenzo Di Nunno, Matteo Santoni, Alessia Cimadamore, Marina Scarpelli, Antonio Lopez-Beltran, Liang Cheng, Cinzia Mariani, Nicola Battelli, Rodolfo Montironi, Francesco Massari

Research output: Contribution to journalReview article

Abstract

Introduction: Knowledge of the complex biology of prostate cancer is constantly growing, opening the field up to new therapeutic advances. The selection of patients on the basis of prognostic and predictive biomarkers is a challenging and emerging clinical need, not yet completely fulfilled. In this scenario, liquid biopsy offers a noninvasive and attractive approach to give important information about tumor biology and eventual resistance to treatments. Areas covered: The aim of this review of the literature is to evaluate the current knowledge and the promising value of liquid biopsy in prostate cancer. Circulating tumor cells and circulating tumor DNA identified by liquid biopsies are currently under evaluation to guide therapeutic decisions in prostate cancer management, even though practical applications of these approaches are still very limited. We examined the current areas of interest in which circulating tumor cells and circulating tumor DNA are being investigated, such as their prognostic and predictive role in response to chemotherapy or androgen receptor signaling inhibition, especially in the castration-resistant setting. Expert opinion: As the body of knowledge on liquid biopsy rapidly grows, we need to identify which can be the real applications of this technique in clinical practice and to overcome the problems that are limiting its routinely use.

Original languageEnglish (US)
JournalExpert Review of Molecular Diagnostics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Prostatic Neoplasms
Circulating Neoplastic Cells
Biopsy
Neoplasms
Castration
DNA
Expert Testimony
Androgen Receptors
Patient Selection
Therapeutics
Biomarkers
Drug Therapy

Keywords

  • castration resistant prostate cancer
  • Cell free DNA (cfDNA)
  • circulating tumor cell (CTC)
  • circulating tumor DNA (ctDNA)
  • liquid biopsy
  • prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. / Mollica, Veronica; Di Nunno, Vincenzo; Santoni, Matteo; Cimadamore, Alessia; Scarpelli, Marina; Lopez-Beltran, Antonio; Cheng, Liang; Mariani, Cinzia; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco.

In: Expert Review of Molecular Diagnostics, 01.01.2019.

Research output: Contribution to journalReview article

Mollica, V, Di Nunno, V, Santoni, M, Cimadamore, A, Scarpelli, M, Lopez-Beltran, A, Cheng, L, Mariani, C, Battelli, N, Montironi, R & Massari, F 2019, 'An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer', Expert Review of Molecular Diagnostics. https://doi.org/10.1080/14737159.2019.1684265
Mollica, Veronica ; Di Nunno, Vincenzo ; Santoni, Matteo ; Cimadamore, Alessia ; Scarpelli, Marina ; Lopez-Beltran, Antonio ; Cheng, Liang ; Mariani, Cinzia ; Battelli, Nicola ; Montironi, Rodolfo ; Massari, Francesco. / An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. In: Expert Review of Molecular Diagnostics. 2019.
@article{48db1c5e2fc349ebb50e24f1e7888849,
title = "An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer",
abstract = "Introduction: Knowledge of the complex biology of prostate cancer is constantly growing, opening the field up to new therapeutic advances. The selection of patients on the basis of prognostic and predictive biomarkers is a challenging and emerging clinical need, not yet completely fulfilled. In this scenario, liquid biopsy offers a noninvasive and attractive approach to give important information about tumor biology and eventual resistance to treatments. Areas covered: The aim of this review of the literature is to evaluate the current knowledge and the promising value of liquid biopsy in prostate cancer. Circulating tumor cells and circulating tumor DNA identified by liquid biopsies are currently under evaluation to guide therapeutic decisions in prostate cancer management, even though practical applications of these approaches are still very limited. We examined the current areas of interest in which circulating tumor cells and circulating tumor DNA are being investigated, such as their prognostic and predictive role in response to chemotherapy or androgen receptor signaling inhibition, especially in the castration-resistant setting. Expert opinion: As the body of knowledge on liquid biopsy rapidly grows, we need to identify which can be the real applications of this technique in clinical practice and to overcome the problems that are limiting its routinely use.",
keywords = "castration resistant prostate cancer, Cell free DNA (cfDNA), circulating tumor cell (CTC), circulating tumor DNA (ctDNA), liquid biopsy, prostate cancer",
author = "Veronica Mollica and {Di Nunno}, Vincenzo and Matteo Santoni and Alessia Cimadamore and Marina Scarpelli and Antonio Lopez-Beltran and Liang Cheng and Cinzia Mariani and Nicola Battelli and Rodolfo Montironi and Francesco Massari",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14737159.2019.1684265",
language = "English (US)",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

AU - Mollica, Veronica

AU - Di Nunno, Vincenzo

AU - Santoni, Matteo

AU - Cimadamore, Alessia

AU - Scarpelli, Marina

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Mariani, Cinzia

AU - Battelli, Nicola

AU - Montironi, Rodolfo

AU - Massari, Francesco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Knowledge of the complex biology of prostate cancer is constantly growing, opening the field up to new therapeutic advances. The selection of patients on the basis of prognostic and predictive biomarkers is a challenging and emerging clinical need, not yet completely fulfilled. In this scenario, liquid biopsy offers a noninvasive and attractive approach to give important information about tumor biology and eventual resistance to treatments. Areas covered: The aim of this review of the literature is to evaluate the current knowledge and the promising value of liquid biopsy in prostate cancer. Circulating tumor cells and circulating tumor DNA identified by liquid biopsies are currently under evaluation to guide therapeutic decisions in prostate cancer management, even though practical applications of these approaches are still very limited. We examined the current areas of interest in which circulating tumor cells and circulating tumor DNA are being investigated, such as their prognostic and predictive role in response to chemotherapy or androgen receptor signaling inhibition, especially in the castration-resistant setting. Expert opinion: As the body of knowledge on liquid biopsy rapidly grows, we need to identify which can be the real applications of this technique in clinical practice and to overcome the problems that are limiting its routinely use.

AB - Introduction: Knowledge of the complex biology of prostate cancer is constantly growing, opening the field up to new therapeutic advances. The selection of patients on the basis of prognostic and predictive biomarkers is a challenging and emerging clinical need, not yet completely fulfilled. In this scenario, liquid biopsy offers a noninvasive and attractive approach to give important information about tumor biology and eventual resistance to treatments. Areas covered: The aim of this review of the literature is to evaluate the current knowledge and the promising value of liquid biopsy in prostate cancer. Circulating tumor cells and circulating tumor DNA identified by liquid biopsies are currently under evaluation to guide therapeutic decisions in prostate cancer management, even though practical applications of these approaches are still very limited. We examined the current areas of interest in which circulating tumor cells and circulating tumor DNA are being investigated, such as their prognostic and predictive role in response to chemotherapy or androgen receptor signaling inhibition, especially in the castration-resistant setting. Expert opinion: As the body of knowledge on liquid biopsy rapidly grows, we need to identify which can be the real applications of this technique in clinical practice and to overcome the problems that are limiting its routinely use.

KW - castration resistant prostate cancer

KW - Cell free DNA (cfDNA)

KW - circulating tumor cell (CTC)

KW - circulating tumor DNA (ctDNA)

KW - liquid biopsy

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85074767449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074767449&partnerID=8YFLogxK

U2 - 10.1080/14737159.2019.1684265

DO - 10.1080/14737159.2019.1684265

M3 - Review article

C2 - 31640441

AN - SCOPUS:85074767449

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

ER -